NCT05440591 (DMVascular) is a Phase 4 clinical trial of Dapagliflozin in Diabetes, sponsored by Tan Tock Seng Hospital.

Who is sponsoring NCT05440591?

NCT05440591 is sponsored by Tan Tock Seng Hospital.

What drugs are being tested in NCT05440591?

Interventions in NCT05440591: Dapagliflozin, MetFORMIN 500 Mg Oral Tablet, Dapagliflozin / metFORMIN Pill.

Is NCT05440591 still recruiting?

NCT05440591 is currently status unknown. Last updated 1 July 2022.

Last reviewed 2022-07-01 · How we verify

NCT05440591: DMVascular

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

Status unknown Phase 4 Last updated 1 July 2022

What this trial tests

Phase 4 trial testing Dapagliflozin in Diabetes in 150 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
10 May 2023

10 May 2023

Quick facts

Lead sponsor	Tan Tock Seng Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 April 2019
Primary completion	10 May 2023
Estimated completion	10 May 2023
Sites	1 location across Singapore

Drugs / interventions tested

Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
MetFORMIN 500 Mg Oral Tablet — full drug profile →
Dapagliflozin / metFORMIN Pill — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Tan Tock Seng Hospital

Who can join

Adults 30 to 65, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dapagliflozin

Trials testing the same drug.

NCT07491042 — Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. · NA · recruiting
NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07239011 — Dapagliflozin in Depression · Phase 1, PHASE2 · recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Tan Tock Seng Hospital trials

Trials by the same sponsor.

NCT07078240 — Examining Nurses' Trust and Acceptance of FAIR, an AI-powered Falls Risk Recommender · NA · not yet recruiting
NCT07257341 — Pilot Study of Normative Range of Field of Binocular Single Vision in Adults in Singapore · recruiting
NCT07151729 — Use of Anodal tDCS to Enhance Upper Limb Recovery in Stroke · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
NCT07255859 — CRYSTALSIGHT Cohort 2.0 · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05440591 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tan Tock Seng Hospital
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05440591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing